Home » Uncategorized (Page 209)
Category Archives: Uncategorized
New Drug Ganetespib May Help Fight Certain Advanced Lung Cancers

ganetespib
STA 9090, cas no 888216-25-9
read all at
http://www.drugs.com/news/new-may-help-fight-certain-advanced-lung-cancers-44819.html
by
WORLD DRUG TRACKER
DR ANTHONY CRATO
All Yоu Nееd Tо Knоwn Abоut Hepatitis C
All Yоu Nееd Tо Knоwn Abоut Hepatitis C
Thе mоѕt fearsome оf аll types оf hepatitis іѕ thе hepatitis C. Thіѕ disease, hepatitis C hаѕ bееn considered bу mаnу specialists tо bе аn epidemic. It іѕ аlѕо knоwn аѕ а silent illness, bесаuѕе уоu саn gеt hepatitis C fоr mаnу years аnd nоt еvеn knоw that. Studies hаvе аlѕо shown thаt аlmоѕt а thіrd оf chronic hepatits C patients will, аt ѕоmе point, suffer frоm symptoms thаt mау threaten thеіr lives.
Hepatitis C саn bе developed bу infection wіth thе hepatitis C virus, whісh аt fіrѕt wаѕ related tо intravenous drugs оr blood transfusions. Mаnу years аftеr thе hepatitis C affected people, іtѕ extent wаѕ knоw fоr а fact. Thаt happened whеn thе fіrѕt blood test fоr detecting thе hepatitis C virus wаѕ available. Mаnу studies hаvе shown thаt іn thе fіrѕt years оf hepatitis C, mоrе thаn а thіrd оf thе patients developed cirrhosis аnd…
View original post 333 more words
Turmeric- Nature’s Ibuprofen, But WAY Better
Turmeric (a plant often used as a spice that can be found in any grocery store) is likely the most common herbal supplement I recommend to my patients. Non steroidal anti inflammatory drugs (such as ibuprofen, advil, motrin, aleve, aspirin) are some of the most commonly used drugs, both by physicians and over the counter. However, their serious side effects are well known and feared by physicians. They are one of the leading causes of stomach and intestinal ulcers and can cause kidney failure. They are usually safe is short courses but for people with chronic pain it becomes a real problem.
Turmeric however has been used in traditional Indian (Ayurvedic) and Chinese medicine for hundreds (possibly thousands) of years for its pain relieving and anti-inflammatory qualities. A study was done in 2011 in the journal Inflammation that looked at the anti-inflammatory capability of turmeric vs ginger vs indomethacin (a…
View original post 256 more words
Property-based lead optimization software for chemists
Property-based lead optimization software for chemists
- Draw your compound and indicate a substituent(s) for modification
- Define the desired property profile (based on PhysChem, ADME/Tox parameters)
- Review the list of automatically selected substituent
- Generate analogs at the click of a button
Full property profiles on-the-fly; tools to review, sort and filter results; and the capability to include in-house models. Software that helps you do it ALL in one intuitive, user-friendly interface!
Watch the Movie
click here-http://www.acdlabs.com/comm/leadop/
…..
Lucentis rival one step away from NHS approval
Bayer’s Eylea (aflibercept),
lucentis, novartis
http://www.pharmatimes.com/Article/13-05-31/Lucentis_rival_one_step_away_from_NHS_approval.aspx
http://www.bioportfolio.com/news/article/1484477/Lucentis-rival-one-step-away-from-NHS-approval.html
Aflibercept is a fusion protein approved in the United States for the treatment of wet macular degeneration and metastatic colorectal cancer.
It is an inhibitor of vascular endothelial growth factor.It is designed to bind to VEGF-A, VEGF-B, and placental growth factor (a.k.a PIGF, gene symbol PGF)
Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals.
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment (Fab) derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Ranibizumab sells for $1,593 per dose, compared to bevacizumab, which can be prepared for macular degeneration treatment in doses that cost $42. Clinical trials have shown both to be equally effective; however there were some reports of infection after dividing bevacizumab into smaller doses.
Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis,under the brand name Lucentis.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....











